ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
The KW18 peptide acts as a dual antimicrobial and immunomodulatory therapeutic candidate in the context of antimicrobial resistance.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHealthcare-associated infections and antimicrobial resistance present major challenges worldwide, especially for immunocompromised patients. This study aimed to evaluate the antimicrobial, antibiofilm, and immunomodulatory properties of KW18, a synthetic peptide (NH₂-KWIRRIIRRYVCFFRKFI-COOH) designed through bioinformatics to target multidrug-resistant bacteria and fungi, and to determine whether KW18 could serve as a dual-action therapy with potent microbicidal and anti-inflammatory effects.
methodsKW18 was tested against Gram-positive and Gram-negative bacteria (Staphylococcus aureus, Pseudomonas aeruginosa) and fungi (Candida glabrata, C. tropicalis). MIC and MBC assays, time-kill curves, and checkerboard synergy tests were performed. Its antibiofilm activity was evaluated on mature biofilms. Membrane disruption was assessed using Sytox™ Green and ergosterol-binding assays. Immunomodulatory effects were analyzed in LPS-stimulated BV-2 microglial cells by measuring nitric oxide, IL-6, and IL-10 levels, and cytotoxicity was evaluated with cell viability assays.
resultsKW18 exhibited potent antimicrobial activity, with low MIC and MBC values across all strains, and retained antifungal effects even in the presence of ergosterol or sorbitol. Time-kill studies showed rapid, concentration-dependent microbicidal effects. The peptide worked synergistically with ciprofloxacin and amphotericin B, effectively inhibiting and eliminating mature biofilms and, in some cases, outperforming conventional treatments. Mechanistic tests confirmed membrane disruption. In BV-2 cells, KW18 reduced nitric oxide and IL-6 while increasing IL-10, all while maintaining over 85% cell viability, with a lower IC₅₀ for NO suppression than dexamethasone.
conclusionKW18 demonstrates strong antimicrobial, antibiofilm, and immunomodulatory activities, supporting its potential as a promising dual-function therapeutic candidate for resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.